Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 2/20 | 0.39 |
| ▸ | FASN | P49327 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3550519 | 0.88 | CDC25A (0.49) | ALDH1A1NPSR1KDM4ETSHRHSD17B10 | |
| SCHEMBL3549221 | 0.88 | KMT2A (0.40) | ALDH1A1NPSR1KDM4ETSHRHSD17B10 | |
| SCHEMBL2399858 | 0.87 | ALDH1A1 (0.40) | ALDH1A1NPSR1KDM4ETSHRHSD17B10 | |
| SCHEMBL3550580 | 0.85 | ALDH1A1 (0.39) | ALDH1A1NPSR1KDM4ETSHRHSD17B10 | |
| SCHEMBL3547560 | 0.84 | KDM4E (0.45) | ALDH1A1NPSR1KDM4ETSHRHSD17B10 | |
| SCHEMBL2400338 | 0.81 | CDC25A (0.44) | ALDH1A1NPSR1KDM4ETSHRHSD17B10 | |
| SCHEMBL3547852 | 0.77 | MALT1 (0.49) | ALDH1A1NPSR1KDM4ETSHRFASN | |
| SCHEMBL3547580 | 0.77 | ALDH1A1 (0.45) | ALDH1A1NPSR1KDM4ETSHRHSD17B10 | |
| SCHEMBL2399861 | 0.76 | ALDH1A1 (0.40) | ALDH1A1NPSR1KDM4ETSHRHSD17B10 | |
| SCHEMBL3552014 | 0.73 | RECQL (0.38) | ALDH1A1NPSR1NPY5RKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317658-A1 | 4,7-Dioxobenzothiazole-2-Carboxamide Derivatives, Their Preparation And Their Therapeutic Uses | IPSEN PHARMA S.A.S. (FR) | 2010-12-16 | — | — | US | claimed |
| US-7795284-B2 | 4,7-dioxobenzothiazole-2-carboxamide derivatives, their preparation and their therapeutic uses | IPSEN PHARMA S.A.S. (FR) | 2010-09-14 | — | — | US | claimed |
| EP-1814879-B1 | DERIVATIVES OF 4,7-DIOXOBENZOTHIAZOLE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND THERAPEUTIC USES OF SAME | SOD CONSEILS RECH APPLIC (FR) | 2008-09-24 | — | — | EP | claimed |
| US-20070244186-A1 | 4, 7-Dioxobenzothiazole-2-Carboxamide Derivatives, Their Preparation and Their Therapeutic Uses | IPSEN PHARMA S.A.S. (FR) | 2007-10-18 | — | — | US | claimed |
| EP-1814879-A1 | DERIVATIVES OF 4,7-DIOXOBENZOTHIAZOLE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND THERAPEUTIC USES OF SAME | Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S) SAS (FR) | 2007-08-08 | — | — | EP | claimed |
| WO-2006051202-A1 | DERIVATIVES OF 4,7-DIOXOBENZOTHIAZOLE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND THERAPEUTIC USES OF SAME | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) SAS (FR) | 2006-05-18 | — | — | WO | claimed |
| US-20100317658-A1 | 4,7-Dioxobenzothiazole-2-Carboxamide Derivatives, Their Preparation And Their Therapeutic Uses | IPSEN PHARMA S.A.S. (FR) | 2010-12-16 | — | — | US | disclosed |
| US-7795284-B2 | 4,7-dioxobenzothiazole-2-carboxamide derivatives, their preparation and their therapeutic uses | IPSEN PHARMA S.A.S. (FR) | 2010-09-14 | — | — | US | disclosed |
| EP-1814879-B1 | DERIVATIVES OF 4,7-DIOXOBENZOTHIAZOLE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND THERAPEUTIC USES OF SAME | SOD CONSEILS RECH APPLIC (FR) | 2008-09-24 | — | — | EP | disclosed |
| US-20070244186-A1 | 4, 7-Dioxobenzothiazole-2-Carboxamide Derivatives, Their Preparation and Their Therapeutic Uses | IPSEN PHARMA S.A.S. (FR) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244186-A1 | 4, 7-Dioxobenzothiazole-2-Carboxamide Derivatives, Their Preparation and Their Therapeutic Uses | CDC25C, CDC25A, CDC25B | ALDH1A1 2011/4885NPSR1 3944/4885KDM4E 723/4885 |
| US-20100317658-A1 | 4,7-Dioxobenzothiazole-2-Carboxamide Derivatives, Their Preparation And Their Therapeutic Uses | CDC25C, CDC25A, CDC25B | ALDH1A1 2011/4885NPSR1 3944/4885KDM4E 723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.